Citi and J.P. Morgan analysts commented bullishly on obesity...

Citi and J.P. Morgan analysts commented bullishly on obesity treatment market, predicting a 'turbocharged' outlook based on presented data. They expect the market to hit $71 billion by 2032 with Novo and Eli Lilly owning about 90%.